Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

The tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA) causes dramatic haemorrhagic necrosis in murine tumours, but activity is seen only at doses close to the toxic limit. This study investigates two approaches for increasing the therapeutic ratio of DMXAA. The first approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J., Wilson, W. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063102/
https://www.ncbi.nlm.nih.gov/pubmed/9716024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063102/
https://www.ncbi.nlm.nih.gov/pubmed/9716024

Ejemplares similares